Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Net Income (2022 - 2025)

Historic Net Income for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$34.4 million.

  • Century Therapeutics' Net Income fell 1023.51% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.5 million, marking a year-over-year increase of 7961.75%. This contributed to the annual value of -$126.6 million for FY2024, which is 739.71% up from last year.
  • According to the latest figures from Q3 2025, Century Therapeutics' Net Income is -$34.4 million, which was down 1023.51% from -$32.5 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Net Income ranged from a high of $76.6 million in Q1 2025 and a low of -$39.4 million during Q4 2023
  • Its 4-year average for Net Income is -$25.6 million, with a median of -$31.7 million in 2022.
  • As far as peak fluctuations go, Century Therapeutics' Net Income crashed by 2436.4% in 2023, and later skyrocketed by 37282.45% in 2025.
  • Over the past 4 years, Century Therapeutics' Net Income (Quarter) stood at -$31.7 million in 2022, then fell by 24.36% to -$39.4 million in 2023, then grew by 8.45% to -$36.1 million in 2024, then grew by 4.58% to -$34.4 million in 2025.
  • Its Net Income was -$34.4 million in Q3 2025, compared to -$32.5 million in Q2 2025 and $76.6 million in Q1 2025.